CliffBio
small molecule

VITEKTA

ELVITEGRAVIR

Loss of exclusivityApril 2027latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameVITEKTA
Active ingredientELVITEGRAVIR
Strength150MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2014
Marketing statusDISCN

Listed patents

PatentExpiresType
7635704*PEDApril 2027—
8981103*PEDApril 2027—
7176220*PEDFebruary 2027—
7635704October 2026substance, product
8981103October 2026substance, product
7176220August 2026substance, product

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VITEKTA patent cliff — loss of exclusivity April 2027 | CliffBio